Sequana Medical

Innovators in the
management of liver disease

Sequana Medical is a commercial stage medical device company and an innovator in the management of liver disease. The first product, alfapump®, is a fully implantable, programmable, transcutaneously-charged, battery-powered pump for the management of refractory ascites (chronic fluid build-up in the abdomen).
Through the experience from the design, development, manufacture and commercialisation of the alfapump, together with the extensive intellectual property portfolio, Sequana Medical is developing an enabling platform for the management of heart failure and other fluid-imbalance disorders

The alfapump® System

An innovative system for the automatic and continual removal of ascites

The alfapump® is a fully implanted, automatic battery-operated pump, charged through the skin, that automaticallly and continually moves ascites from the abdominal cavity to the bladder, where it is excreted naturally from the body for improved patient’s quality of life

About Sequana Medical

Research and development

Sequana Medical

Enabling platform for fluid imbalance disorders

Through the experience from the design, development, manufacture and commmercialisation of the alfapump, together with the extensive intellectual property portfolio, Sequana Medical has established an
enabling platform for the management of heart failure and other fluid-imbalance disorders

Liver Disease

Large and Growing Market

Liver disease is a large and growing market, driven by lifestyles (alcohol, viral disease and obesity), aging populations and growth in emerging markets.
Incidence of Non-alcoholic Steatohepatic (NASH) is forecast to grow dramatically in the coming years
Liver cirrhosis results from liver disease and refractory ascites is the leading complication of liver cirrhosis.
The alfapump® provides significant benefits to patients, clinicians and healthcare systems in the treatment of refractory ascites.

0
years of cumulative pumping time
0
alfapump Implantations
+0
Pumped liquid (Lt)

Recent News

All news

Our investors